Uncategorized

UCB plots epilepsy expansion with $650M Neurona cell therapy acquisition

Published

on

UCB plans to pay $650 million to Neurona Therapeutics in a bid to broaden its clinical-stage epilepsy portfolio.

The deal comes with as much as $500 million in milestone payments.

Neurona is developing a treatment …

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version